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Background: While the results from randomized controlled trials (RCTs) show a significant reduction in major cardiovascular (CV) events with early 
use of clopidogrel plus aspirin (C+A) in acute coronary syndrome (ACS) patients, the benefit of C+A use is less clear in non-ACS patients. The aim of 
this analysis is to show the benefits and risks of early C+A in high-risk patients (ACS and non-ACS) during long-term follow-up.
Methods: A meta-analysis of 5 RCTs (CURE, CREDO, CLARITY, COMMIT and the symptomatic cohort of CHARISMA) comprising 76,174 patients with 
established vascular disease was performed using random effects model. The composite outcome was CV mortality, myocardial infarction (MI) and 
stroke. Individual outcomes of all-cause mortality, CV mortality, MI and stroke were also assessed, as was major bleeding as a safety outcome.
Results: For C+A versus A alone, there was a 15% reduction in the odds ratio (OR) for the composite outcome (OR = 0.85; 95% CI 0.79, 0.91, P 
<0.0001) [see Fig], a 7% decrease for all-cause mortality (OR = 0.93; 95% CI 0.88, 0.98; P = 0.009] and a 7% decrease for CV mortality (OR = 
0.93; 95% CI 0.87, 0.98; P = 0.01]. For MI the OR was reduced by 18% (OR = 0.82; 95% CI 0.75, 0.88; P <0.00001) and for stroke by 16% (OR = 
0.84; 95% CI 0.74, 0.95; P = 0.005). However, C+A significantly increased the odds of major bleeding by 17% (OR = 1.17; 95% CI 1.02, 1.33; P = 
0.02).
Conclusion: C+A significantly reduces both composite and individual CV outcomes in high-risk patients, although major bleeding is increased.
